Touchlight To Disrupt DNA Market With Synthetic Manufacturing
Touchlight Positions Itself To Meet Coming Demand For ‘100s of kilograms of DNA’
Touchlight has secured £42m ($60m) in funding to support efforts to triple its manufacturing capacity of synthetic DNA based on the company’s proprietary dbDNA platform – an enzyme made minimal linear DNA vector. The completed facility will have the capacity to produce 1kg of GMP DNA per month, enough for one billion COVID-19 vaccine doses.
You may also be interested in...
BioInnovation Institute chief business officer Bobby Soni shares how the life sciences incubator sources entrepreneurs and science globally, and the range of tools it provides to translate this into commercially viable companies.
Lithuania’s life sciences sector has harnessed the country’s talent, infrastructure and government support to realize a decade of unprecedented growth. With the industry now maturing, can the Baltic state overcome challenges to become a significant European player?
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.